AstraZeneca Bolsters Late-Stage Cardiovascular Disease Pipeline with Omthera Pharmaceuticals Purchase
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 6 (Table of Contents)
Published: 19 Jun-2013
DOI: 10.3833/pdr.v2013.i6.1952 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In its second cardiovascular disease-focused purchase of 2013, AstraZeneca has agreed to acquire Omthera Pharmaceuticals for approximately US$323 M plus Contingent Value Rights that equate to approximately US$120 M in total...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS